journal
MENU ▼
Read by QxMD icon Read
search

Cancer Discovery

journal
https://www.readbyqxmd.com/read/28526740/midostaurin-gets-fda-nod-for-aml
#1
(no author information available yet)
The FDA has approved the small-molecule inhibitor midostaurin in combination with chemotherapy to treat acute myeloid leukemia. It is the first approved drug for the disease that specifically targets FLT3 mutations, which occur in about a quarter of all AML cases and are associated with particularly poor outcomes.
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28526739/azd5363-has-clinical-activity-in-patients-with-akt1-mutant-solid-tumors
#2
(no author information available yet)
Targeting mutant AKT1 has antitumor activity in a basket trial of patients with AKT1-mutant tumors.
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28526738/hpv-vaccine-slashes-rates-of-oral-infection
#3
(no author information available yet)
Vaccination against human papillomavirus (HPV) reduces the prevalence of oral infection by an estimated 88% among young adults in the United States, a protection that could help reduce rates of HPV-related oropharyngeal cancers, according to data that will be presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL. However, the population-level benefit will remain low unless more people get vaccinated.
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28526737/a-wnt-producing-niche-drives-lung-adenocarcinoma
#4
(no author information available yet)
Lung adenocarcinomas contain cells that exhibit high WNT signaling and cells that provide WNT ligands.
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28526736/chd4-mediated-dna-hypermethylation-promotes-colorectal-cancer
#5
(no author information available yet)
CHD4 maintains epigenetic silencing of tumor suppressor genes to promote tumorigenesis.
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28526735/activated-notch-induced-intratumoral-heterogeneity-drives-lung-cancer
#6
(no author information available yet)
Activated NOTCH signaling is both tumor-suppressive and protumorigenic in SCLC.
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28526734/brigatinib-achieves-whole-body-and-intracranial-responses
#7
(no author information available yet)
Brigatinib is tolerable and has antitumor activity in crizotinib-resistant ALK-positive NSCLC.
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28526733/discovery-and-optimization-of-hkt288-a-cadherin-6-targeting-adc-for-the-treatment-of-ovarian-and-renal-cancer
#8
Carl U Bialucha, Scott D Collins, Xiao Li, Parmita Saxena, Xiamei Zhang, Clemens Dürr, Bruno LaFont, Pierric Prieur, Yeonju Shim, Rebecca Mosher, David Lee, Lance Ostrom, Tiancen Hu, Sanela Bilic, Ivana Liric Rajlic, Vladimir Capka, Wei Jiang, Joel P Wagner, GiNell Elliott, Artur Veloso, Jessica C Piel, Meghan M Flaherty, Keith G Mansfield, Emily K Meseck, Tina Rubic-Schneider, Anne Serdakowski London, William R Tschantz, Markus Kurz, Duc Nguyen, Aaron Bourret, Matthew J Meyer, Jason E Faris, Mary J Janatpour, Vivien W Chan, Nicholas C Yoder, Kalli C Catcott, Molly A McShea, Xiuxia Sun, Hui Gao, Juliet Williams, Francesco Hofmann, Jeffrey A Engelman, Seth A Ettenberg, William R Sellers, Emma Lees
Despite an improving therapeutic landscape, significant challenges remain in treating the majority of advanced ovarian and renal cancer patients. We identified the cell-cell adhesion molecule cadherin-6 (CDH6) as a lineage gene having significant differential expression in ovarian and kidney cancer. HKT288 is an optimized CDH6-targeting DM4-based antibody drug conjugate (ADC) developed for the treatment of these diseases. Our study provides mechanistic evidence supporting the importance of linker choice for optimal anti-tumor activity and highlights CDH6 as a novel antigen for biotherapeutic development...
May 19, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28522683/congress-oks-2-billion-boost-for-the-nih
#9
(no author information available yet)
President Donald Trump last week signed a $1.1 trillion spending bill for fiscal year 2017, including a welcome $2 billion boost for the NIH that will support former Vice President Joe Biden's Cancer Moonshot initiative, among other priorities. However, researchers who rely heavily on NIH grant funding remain concerned about proposed cuts for 2018.
May 18, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28522682/regorafenib-approved-for-liver-cancer
#10
(no author information available yet)
The FDA recently expanded label indications for regorafenib to include treating patients with advanced hepatocellular carcinoma whose disease has progressed on the standard of care, sorafenib. Until now, these patients have had no other treatment options. Regorafenib is the first drug to be approved for liver cancer in a decade.
May 18, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28515055/exome-sequencing-of-african-american-prostate-cancer-reveals-loss-of-function-erf-mutations
#11
Franklin W Huang, Juan Miguel Mosquera, Andrea Garofalo, Coyin Oh, Maria Baco, Ali Amin-Mansour, Bokang Rabasha, Samira Bahl, Stephanie A Mullane, Brian D Robinson, Saud Aldubayan, Francesca Khani, Beerinder Karir, Eejung Kim, Jeremy Chimene-Weiss, Matan Hofree, Alessandro Romanel, Joseph R Osborne, Jong Wook Kim, Gissou Azabdaftari, Anna Woloszynska-Read, Karen Sfanos, Angelo M De Marzo, Francesca Demichelis, Stacey Gabriel, Eliezer M Van Allen, Jill Mesirov, Pablo Tamayo, Mark A Rubin, Isaac J Powell, Levi A Garraway
African-American men have the highest incidence and mortality from prostate cancer. Whether a biological basis exists for this disparity remains unclear. Exome sequencing (n=102) and targeted validation (n = 90) of localized primary hormone-naïve prostate cancer in African-American men identified several gene mutations not previously observed in this context, including recurrent loss-of-function mutations in ERF, an ETS transcriptional repressor, in 5% of cases. Analysis of existing prostate cancer cohorts revealed ERF deletions in 3% of primary prostate cancers and mutations or deletions in ERF in 3-5% of lethal castration-resistant prostate cancers...
May 17, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28500029/cytosine-methylation-alters-transcription-factor-dna-binding
#12
(no author information available yet)
CpG methylation promotes binding of a subset of transcription factors and inhibits binding of others.
May 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28500028/chemotherapy-activated-caspase-3-cleaves-gsdme-to-drive-pyroptosis
#13
(no author information available yet)
GSMDE promotes a switch of chemotherapy-mediated cell death from apoptosis to pyroptosis.
May 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28500027/engineering-car-t-cells-with-biomaterials
#14
(no author information available yet)
Incorporating biomaterials into the design of CAR T cells may yield new, improved versions of this immunotherapy. Two preclinical studies indicate the potential of using biodegradable nanoparticles to program circulating T cells into CAR T cells in situ, and delivering these therapeutic cells directly to solid tumors via small dissolvable sponges.
May 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28500026/the-hect-e3-ubiquitin-ligase-wwp2-is-autoinhibited-by-a-peptide-linker
#15
(no author information available yet)
Peptide linkers that tether WWP2 WW domains lock the HECT domain in an inactive conformation.
May 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28500025/varlilumab-is-safe-and-active-in-patients-with-advanced-solid-tumors
#16
(no author information available yet)
Varlilumab activates the CD27 pathway in T cells to promote antitumor activity in solid tumors.
May 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28500024/anticancer-sulfonamides-induce-splicing-factor-rbm39-degradation
#17
(no author information available yet)
Anticancer sulfonamides produce aberrant splicing by inducing degradation of the splicing factor RBM39.
May 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28495849/neoadjuvant-trials-in-er-breast-cancer-a%C3%A2-tool-for-acceleration-of-drug-development-and-discovery
#18
REVIEW
Angel L Guerrero-Zotano, Carlos L Arteaga
Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER(+)) breast cancers, however, use of this strategy has been challenging because of the lack of validated surrogates of long-term efficacy and the overall good prognosis of the majority of patients with this cancer subtype...
May 11, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28487325/chromosome-instability-drives-tumor-evolution
#19
(no author information available yet)
A prospective study of patients with non-small cell lung cancer undergoing treatment reveals that chromosomal instability and tumor heterogeneity drive disease recurrence. Researchers involved in the TRACERx trial documented that genetic diversity by sequencing multiple regions of the primary tumor and then created bespoke ctDNA tests that allowed for early detection of relapse and metastasis.
May 9, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28476754/the-rna-binding-protein-syncrip-promotes-leukemogenesis
#20
(no author information available yet)
Depletion of the RNA-binding protein (RBP) SYNCRIP promotes leukemic cell differentiation and apoptosis.
May 5, 2017: Cancer Discovery
journal
journal
43599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"